Disease Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
BRAF V600X Vemurafenib cholangiocarcinoma predicted - sensitive detail...
FGFR2 fusion Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 mutant Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 fusion FGFR2 V564F Infigratinib cholangiocarcinoma predicted - resistant detail...
IDH1 mutant Ivosidenib cholangiocarcinoma sensitive detail...
FGFR2 fusion Futibatinib cholangiocarcinoma sensitive detail...
FGFR2 rearrange Futibatinib cholangiocarcinoma sensitive detail...
FGFR2 rearrange FGFR2 amp Futibatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 rearrange Pemigatinib cholangiocarcinoma sensitive detail...
FGFR2 mutant Erdafitinib cholangiocarcinoma predicted - sensitive detail...
FGFR3 mutant Erdafitinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 fusion Erdafitinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 fusion Pemigatinib cholangiocarcinoma sensitive detail...
BRAF V600E Vemurafenib cholangiocarcinoma predicted - sensitive detail...
IDH1 R132C Ivosidenib cholangiocarcinoma sensitive detail...
IDH1 R132S Ivosidenib cholangiocarcinoma sensitive detail...
IDH1 R132L Ivosidenib cholangiocarcinoma sensitive detail...
IDH1 R132G Ivosidenib cholangiocarcinoma sensitive detail...
FGFR3 amp Infigratinib cholangiocarcinoma no benefit detail...
FGFR2 amp Infigratinib cholangiocarcinoma sensitive detail...
BRAF V600E Dabrafenib + Trametinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 fusion ICP-192 cholangiocarcinoma predicted - sensitive detail...
FGFR2 rearrange Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 M537I FGFR2 V564L FGFR2 amp Infigratinib cholangiocarcinoma predicted - resistant detail...
IDH1 R132H Ivosidenib cholangiocarcinoma sensitive detail...
IDH1 R132S Ceralasertib + Olaparib cholangiocarcinoma sensitive detail...
FGFR2 C382R Pemigatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 fusion Lirafugratinib cholangiocarcinoma predicted - sensitive detail...
RET fusion Selpercatinib cholangiocarcinoma sensitive detail...
BRAF V600E Cobimetinib + Vemurafenib cholangiocarcinoma predicted - sensitive detail...
IDH1 R132C Olaparib cholangiocarcinoma no benefit detail...
IDH1 R132C Pamiparib cholangiocarcinoma no benefit detail...
IDH1 R132C Niraparib cholangiocarcinoma no benefit detail...
ARID1B Q127_Q131del IDH1 R132L Niraparib cholangiocarcinoma no benefit detail...
ARID1B Q127_Q131del IDH1 R132L Olaparib cholangiocarcinoma no benefit detail...
ARID1B Q127_Q131del IDH1 R132L Pamiparib cholangiocarcinoma no benefit detail...
MLH1 negative Pembrolizumab cholangiocarcinoma sensitive detail...
MSH6 negative Pembrolizumab cholangiocarcinoma sensitive detail...
FGFR2 I291_Y308del Pemigatinib cholangiocarcinoma predicted - sensitive detail...
BRAF V600E BGB3245 cholangiocarcinoma predicted - sensitive detail...
IDH1 act mut LY3410738 cholangiocarcinoma predicted - sensitive detail...
IDH2 act mut LY3410738 cholangiocarcinoma predicted - sensitive detail...
IDH1 mutant Durvalumab + Olaparib cholangiocarcinoma no benefit detail...
FGFR2 C382R Erdafitinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 act mut Tinengotinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 Y375C Futibatinib cholangiocarcinoma sensitive detail...
FGFR2 H167_N173del Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 N631_M640del Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 I548Wfs*8 Infigratinib cholangiocarcinoma sensitive detail...
FGFR2 I288_D304del Infigratinib cholangiocarcinoma no benefit detail...
FGFR2 C382R Infigratinib cholangiocarcinoma no benefit detail...
FGFR2 K545del Infigratinib cholangiocarcinoma no benefit detail...
FGFR2 S372C Lenvatinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 fusion E7090 cholangiocarcinoma predicted - sensitive detail...
MLH1 negative Nivolumab cholangiocarcinoma predicted - sensitive detail...
FGFR2 C382R Tinengotinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 I291_Y308del FGFR2 N549K Pemigatinib cholangiocarcinoma predicted - resistant detail...
FGFR2 C382R FGFR2 N549D FGFR2 N549H FGFR2 N549K FGFR2 V564L Pemigatinib cholangiocarcinoma predicted - resistant detail...
ATM G1676fs Talazoparib cholangiocarcinoma predicted - sensitive detail...
FGFR1 rearrange Erdafitinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 rearrange Erdafitinib cholangiocarcinoma predicted - sensitive detail...
FGFR3 rearrange Erdafitinib cholangiocarcinoma predicted - sensitive detail...
FGFR2 fusion Gemcitabine + Pemigatinib cholangiocarcinoma sensitive detail...
Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT01174121 Phase II Pembrolizumab Cyclophosphamide + Fludarabine Aldesleukin Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Cancer Recruiting USA 0
NCT01438554 Phase I Pazopanib + Trametinib Phase 1 Study of Pazopanib With GSK1120212 in Advanced Solid Tumors, Enriched With Patients With Differentiated Thyroid Cancer, Soft-tissue Sarcoma, and Cholangiocarcinoma Completed USA 0
NCT01642342 Phase I sEphB4-HSA Recombinant Albumin Fusion Protein sEphB4-HSA in Treating Patients With Metastatic or Recurrent Solid Tumors Terminated USA 0
NCT01695005 Phase I LY3039478 A Study of LY3039478 in Participants With Advanced Cancer Completed USA | GBR | FRA | ESP | DNK | DEU 0
NCT01825603 Phase I ADH-1 + Cisplatin + Gemcitabine ADH-1, Gemcitabine Hydrochloride and Cisplatin in Treating Patients With Metastatic Pancreatic or Biliary Tract Cancer That Cannot Be Removed By Surgery Completed USA 0
NCT01888302 Phase I Cisplatin + Gemcitabine + Sirolimus Sirolimus, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients At High Risk for Cholangiocarcinoma Recurrence After Liver Transplant or Surgery Completed USA 0
NCT02024607 Phase Ib/II Capecitabine + Oxaliplatin Bevacizumab + Napabucasin Napabucasin + Regorafenib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab Napabucasin Fluorouracil + Irinotecan + Leucovorin A Study of BBI608 in Combination With Standard Chemotherapies in Adult Patients With Advanced Gastrointestinal Cancer Completed USA | CAN 0
NCT02052778 Phase Ib/II Futibatinib A Study of TAS-120 in Patients With Advanced Solid Tumors Completed USA | NLD | ITA | GBR | FRA | ESP | DEU | CAN | AUS 4
NCT02053376 Phase II Regorafenib A Phase 2 Trial of Regorafenib as A Single Agent in Advanced and Metastatic Biliary Tract Carcinoma/Cholangiocarcinoma Patients Who Have Failed First-line Chemotherapy Completed USA 0
NCT02128282 Phase Ib/II Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Silmitasertib Study of CX-4945 in Combination With Gemcitabine and Cisplatin for Frontline Treatment of Cholangiocarcinoma Completed USA 2
NCT02150967 Phase II Infigratinib A Phase II, Single Arm Study of BGJ398 in Patients With Advanced Cholangiocarcinoma Terminated USA | ITA | GBR | ESP | DEU | BEL 5
NCT02187848 Phase Ib/II SAR408701 Evaluation of SAR408701 in Patients With Advanced Solid Tumors Terminated USA | FRA | ESP | CAN 1
NCT02232633 Phase II Amcasertib A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer Completed CAN 0
NCT02240238 Phase Ib/II Gemcitabine + NC-6004 Combination Therapy With NC-6004 and Gemcitabine in Advanced Solid Tumors or Non-Small Cell Lung, Biliary and Bladder Cancer Completed USA | ROU | POL | ITA | BGR 0
NCT02393248 Phase Ib/II Cisplatin + Gemcitabine + Pemigatinib Docetaxel + Pemigatinib Pemigatinib + Retifanlimab Pemigatinib + Trastuzumab Epacadostat + Pembrolizumab Open-Label, Dose-Escalation Study of Pemigatinib in Subjects With Advanced Malignancies - (FIGHT-101) Terminated USA | DNK 0
NCT02452970 Phase II RRx-001 Cisplatin + Gemcitabine RRx-001 in Second Line Treatment of Advanced Cholangiocarcinoma Prior to Readministration of First-Line Therapy (EPIC) Terminated USA 0
NCT02479178 Phase II BIND-014 A Study of BIND-014 in Patients With Urothelial Carcinoma, Cholangiocarcinoma, Cervical Cancer and Squamous Cell Carcinoma of the Head and Neck (iNSITE2) Terminated USA 1
NCT02508467 Phase I Fisogatinib A Phase 1 Study of BLU-554 in Patients With Hepatocellular Carcinoma and Cholangiocarcinoma Completed USA | ITA | GBR | FRA | ESP | DEU | CHE 5
NCT02520141 Phase II Ramucirumab Ramucirumab for Advanced Pre-treated Biliary Cancers Completed USA 0
NCT02628067 Phase II Pembrolizumab Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) Recruiting USA | POL | NOR | NLD | ITA | ISR | FRA | ESP | DNK | DEU | BRA | AUS 9
NCT02632305 Phase II Cisplatin + Gemcitabine + Nab-paclitaxel A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer (AX-CSARC) Active, not recruiting CAN 0
NCT02638909 Phase II Ceritinib Study of Oral Ceritinib in Patients With ALK-Activated Gastrointestinal Malignancies Terminated USA 0
NCT02711553 Phase II Ramucirumab Merestinib Cisplatin + Gemcitabine A Study of Ramucirumab (LY3009806) or Merestinib (LY2801653) in Advanced or Metastatic Biliary Tract Cancer Active, not recruiting USA | TUR | SWE | HUN | GBR | FRA | ESP | DNK | DEU | CZE | BEL | AUT | AUS | ARG 4
NCT02784795 Phase I Cisplatin + Gemcitabine + LY3039478 Carboplatin + Gemcitabine + LY3039478 LY3023414 + LY3039478 Abemaciclib + LY3039478 LY3039478 + Taladegib LY3039478 LY3023414 A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors Completed USA | FRA | ESP | DNK 0
NCT02824042 Phase I Anetumab ravtansine + Itraconazole Anetumab ravtansine Thorough ECG (Electrocardiogram) and Drug Interaction Study With Anetumab Ravtansine and Itraconazole Completed USA | NLD | FRA | ESP | BEL | AUS 0
NCT02834013 Phase 0 Ipilimumab + Nivolumab Nivolumab and Ipilimumab in Treating Patients With Rare Tumors Active, not recruiting USA 1
NCT02856568 Phase I Cisplatin + Gemcitabine + Ricolinostat Ricolinostat, Gemcitabine Hydrochloride, and Cisplatin in Treating Patients With Unresectable or Metastatic Cholangiocarcinoma Withdrawn USA 0
NCT02924376 Phase II Pemigatinib Efficacy and Safety of INCB054828 in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy Completed USA | ITA | ISR | GBR | FRA | ESP | DEU | BEL 4
NCT02963831 Phase Ib/II Durvalumab + ONCOS-102 A Phase 1/2 Study to Investigate the Safety, Biologic and Anti-tumor Activity of ONCOS-102 in Combination With Durvalumab in Subjects With Advanced Peritoneal Malignancies Completed USA 0
NCT02982720 Phase II Peginterferon alfa-2b + Pembrolizumab Evaluating Combination Immunotherapy for Advanced Cholangiocarcinoma With Pembrolizumab and PEG-Intron Terminated USA 0
NCT02989857 Phase III Ivosidenib Study of AG-120 in Previously Treated Advanced Cholangiocarcinoma With IDH1 Mutations (ClarIDHy) Completed USA | ITA | GBR | FRA | ESP 1
NCT03093870 Phase II Capecitabine + Varlitinib Capecitabine Varlitinib in Combination With Capecitabine for Advanced or Metastatic Biliary Tract Cancer Completed USA | POL | HUN | ESP | AUS 6
NCT03095781 Phase I Pembrolizumab + XL888 Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal Cancer Completed USA 0
NCT03102320 Phase I Anetumab ravtansine Anetumab ravtansine + Gemcitabine Anetumab ravtansine + Cisplatin Phase 1b Multi-indication Study of Anetumab Ravtansine in Mesothelin Expressing Advanced Solid Tumors (ARCS-Multi) Completed USA | NLD | ITA | GBR | FRA | ESP | CHE | CAN | BEL | AUS 2
NCT03132792 Phase I AFPc332T AFPc332T in Advanced HCC Active, not recruiting USA | GBR | FRA | ESP 0
NCT03144661 Phase I INCB062079 An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies Terminated USA | BEL 0
NCT03201458 Phase II Atezolizumab Atezolizumab + Cobimetinib Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery Completed USA 0
NCT03207347 Phase II Niraparib A Trial of Niraparib in BAP1 and Other DNA Damage Response (DDR) Deficient Neoplasms (UF-STO-ETI-001) Completed USA 0
NCT03212274 Phase II Olaparib Olaparib in Treating Patients With Advanced Glioma, Cholangiocarcinoma, or Solid Tumors With IDH1 or IDH2 Mutations Active, not recruiting USA 0
NCT03230318 Phase II Derazantinib Derazantinib in Subjects With FGFR2 Gene Fusion-, Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma (FIDES-01) Completed USA | ITA | IRL | GBR | FRA | ESP | DEU | CHE | CAN | BEL 1
NCT03250273 Phase II Entinostat + Nivolumab A Clinical Trial of Entinostat in Combination With Nivolumab for Patients With Previously Treated Unresectable or Metastatic Cholangiocarcinoma and Pancreatic Adenocarcinoma Completed USA 0
NCT03257761 Phase I Durvalumab + Guadecitabine Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer Active, not recruiting USA 0
NCT03267940 Phase I Cisplatin + Gemcitabine Atezolizumab + Cisplatin + Gemcitabine + PEGPH20 Cisplatin + Gemcitabine + PEGPH20 Open-Label Study of PEGPH20 With CIS and GEM; PEGPH20 With Atezolizumab, CIS and GEM; and Compared With CIS and GEM Alone in HA-high Subjects With Previously Untreated, Unresectable, Locally Advanced, or Metastatic Intrahepatic and Extrahepatic Cholangiocarcinoma and Gallbladder Adenocarcinoma Terminated USA 2
NCT03329950 Phase I CDX-1140 + CDX-301 CDX-1140 A Study of CDX-1140 as Monotherapy or in Combination in Patients With Advanced Solid Tumors Completed USA 0
NCT03339843 Phase II Abemaciclib Multiorgan Metabolic Imaging Response Assessment of Abemaciclib (MiMe-A) Completed FRA | BEL 0
NCT03368963 Phase Ib/II Liposomal irinotecan + Trifluridine-tipiracil hydrochloride TAS102 in Combination With NAL-IRI in Advanced GI Cancers Recruiting USA 0
NCT03377179 Phase II ABC294640 A Study of ABC294640 in the Treatment of Patients With Advanced Cholangiocarcinoma Completed USA 0
NCT03422679 Phase Ib/II CB-103 Study of CB-103 in Adult Patients With Advanced or Metastatic Solid Tumours and Haematological Malignancies Terminated USA | FRA | ESP | DEU | CHE 1
NCT03517488 Phase I XmAb20717 A Study of XmAb20717 in Subjects With Selected Advanced Solid Tumors (DUET-2) Completed USA 0
NCT03656536 Phase III Pemigatinib Cisplatin + Gemcitabine A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma (FIGHT-302) Active, not recruiting USA | SWE | NOR | NLD | ITA | ISR | IRL | GBR | FRA | FIN | ESP | DNK | DEU | CHE | CAN | BEL | AUT 2
NCT03704480 Phase II Durvalumab + Tremelimumab Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy (IMMUNO-BIL) Active, not recruiting FRA 0
NCT03733990 Phase Ib/II FP-1305 A Study to Evaluate Safety, Tolerability and Preliminary Efficacy of FP-1305 in Cancer Patients (MATINS) Completed USA | NLD | GBR | FRA | FIN | ESP 0
NCT03773302 Phase III Cisplatin + Gemcitabine Infigratinib Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations Terminated USA | ITA | GBR | FRA | ESP | DEU | CAN | BEL | AUS 6
NCT03797326 Phase II Lenvatinib + Pembrolizumab Efficacy and Safety of Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) in Previously Treated Participants With Select Solid Tumors (MK-7902-005/E7080-G000-224/LEAP-005) Completed USA | ITA | ISR | GBR | FRA | ESP | DEU | CHE | CAN | AUS | ARG 6
NCT03872947 Phase I Pembrolizumab + TRK-950 Carboplatin + Gemcitabine + TRK-950 Imiquimod + TRK-950 Paclitaxel + Ramucirumab + TRK-950 Nivolumab + TRK-950 Cisplatin + Gemcitabine + TRK-950 Fluorouracil + Irinotecan + Leucovorin + TRK-950 A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors Recruiting USA | FRA 0
NCT03878095 Phase II Ceralasertib + Olaparib Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant Tumors Active, not recruiting USA 0
NCT03907852 Phase Ib/II Gavocabtagene autoleucel + Ipilimumab + Nivolumab Gavocabtagene autoleucel + Nivolumab Gavocabtagene autoleucel Cyclophosphamide + Fludarabine Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer Active, not recruiting USA | CAN 0
NCT03943004 Phase I DFP-14927 Trial of DFP-14927 in Advanced Solid Tumors Recruiting USA 0
NCT04003636 Phase III Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966) (KEYNOTE-966) Active, not recruiting USA | TUR | NZL | NLD | ITA | ISR | IRL | GBR | FRA | ESP | DEU | CAN | BRA | BEL | AUS | ARG 8
NCT04003896 Phase II Abemaciclib A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma Who Failed Prior First Line Therapy Terminated USA 0
NCT04034238 Phase I LMB-100 + Tofacitinib Mesothelin-Targeted Immunotoxin LMB-100 in Combination With Tofacitinib in Persons With Previously Treated Pancreatic Adenocarcinoma, Cholangiocarcinoma and Other Mesothelin Expressing Solid Tumors Completed USA 0
NCT04057365 Phase II DKN-01 + Nivolumab A Single Arm Phase II Study of the Combination of DKN-01 and Nivolumab in Previously Treated Patients With Advanced Biliary Tract Cancer (BTC) Terminated USA 0
NCT04068194 Phase Ib/II Avelumab Avelumab + Peposertib Testing the Combination of New Anti-cancer Drug Nedisertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies Recruiting USA 0
NCT04088188 Phase I Cisplatin + Gemcitabine + Pemigatinib Cisplatin + Gemcitabine + Ivosidenib Gemcitabine and Cisplatin With Ivosidenib or Pemigatinib for the Treatment of Unresectable or Metastatic Cholangiocarcinoma Terminated USA 0
NCT04137289 Phase I BI 905711 A First-in-human Phase Ia/b, Open Label, Multicentre, Dose Escalation Study of BI 905711 in Patients With Advanced Gastrointestinal Cancers Completed USA | FRA | ESP | DEU | BEL 3
NCT04149691 Phase I CPL304110 Safety, Tolerability and Pharmacokinetics of Oral CPL304110, in Adult Subjects With Advanced Solid Malignancies Recruiting POL 0
NCT04175912 Phase II Carboplatin + MLN4924 + Paclitaxel MLN4924 Testing the Combination of Pevonedistat With Chemotherapy for Bile Duct Cancer of the Liver Active, not recruiting USA 0
NCT04233567 Phase II Infigratinib Infigratinib for the Treatment of Advanced or Metastatic Solid Tumors in Patients With FGFR Gene Mutations Active, not recruiting USA 0
NCT04294576 Phase I BJ-001 + Pembrolizumab BJ-001 Safety Study of BJ-001, and IL-15 Fusion Protein, for Locally Advanced/Metastatic Solid Tumors (FIH) Active, not recruiting USA 0
NCT04301011 Phase Ib/II TBio-6517 Pembrolizumab + TBio-6517 Study of TBio-6517 Given Alone or in Combination With Pembrolizumab in Solid Tumors (RAPTOR) Terminated USA | CAN 1
NCT04306367 Phase II Olaparib + Pembrolizumab Study of Pembrolizumab and Olaparib in Bile Duct Cancer Active, not recruiting USA 0
NCT04396821 Phase I TST001 A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors Active, not recruiting USA 0
NCT04421820 Phase I BOLD-100 + Fluorouracil + Leucovorin + Oxaliplatin BOLD-100 in Combination With FOLFOX for the Treatment of Advanced Solid Tumours Recruiting USA | IRL | CAN 1
NCT04430738 Phase Ib/II Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Fluorouracil + Leucovorin + Oxaliplatin + Pembrolizumab + Trastuzumab + Tucatinib Capecitabine + Oxaliplatin + Trastuzumab + Tucatinib Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers Active, not recruiting USA 1
NCT04430842 Phase I QBS10072S Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of QBS10072S Completed AUS 0
NCT04507503 Expanded access Futibatinib Expanded Access Study of TAS-120 in Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements Approved for marketing USA 0
NCT04521686 Phase I LY3410738 Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations Active, not recruiting USA | FRA | ESP | AUS 5
NCT04565275 Phase Ib/II ICP-192 A Study of ICP-192 in Patients With Advanced Solid Tumors Recruiting USA | AUS 0
NCT04641871 Phase I Sym021 + Sym023 Sym021 + Sym022 Sym021 in Combination With Either Sym022 or Sym023 in Patients With Advanced Solid Tumor Malignancies Completed USA | FRA | ESP | CAN 0
NCT04645160 Phase Ib/II Tivozanib Phase I/II Study Evaluating Safety and Efficacy of Tivozanib (AV-951) in Cholangiocarcinoma Recruiting USA 0
NCT04648319 Phase II Nivolumab A Study of BMS-936558 With SBRT After Induction Chemotherapy in Cholangiocarcinoma Terminated LUX | LBN | BEL 0
NCT04672434 Phase I Sym021 + Sym024 Sym024 Sym024 Monotherapy and in Combination With Sym021 in Patients With Advanced Solid Tumor Malignancies Active, not recruiting USA | CAN 0
NCT04676633 Phase I Cotsiranib Open-Label Study for Safety, Tolerability, PK and Anti-Tumor Activity of STP705 Administered Intratumorally in Cholangiocarcinoma, Hepatocellular Carcinoma or Liver Metastases in Subjects With Advanced/Metastatic or Surgically Unresectable Solid Tumors Who Are Refractory to Standard Therapy Completed USA 0
NCT04677504 Phase II Atezolizumab + Cisplatin + Gemcitabine Atezolizumab + Bevacizumab + Cisplatin + Gemcitabine A Study of Atezolizumab With or Without Bevacizumab in Combination With Cisplatin Plus Gemcitabine in Patients With Untreated, Advanced Biliary Tract Cancer Completed USA | TUR | POL | ITA | GBR | ESP 7
NCT04704154 Phase II Nivolumab + Regorafenib A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors Completed USA | ITA | GBR | FRA | BEL 3
NCT04717375 Phase Ib/II BND-22 Study of SAR444881 Administered Alone and in Combination With Other Therapeutics in Participants With Advanced Solid Tumors Recruiting USA | ISR | GBR | CAN 0
NCT04781192 Phase Ib/II Durvalumab + Regorafenib The Purpose of This Trial is to Determine if Regorafenib Plus Durvalumab (MEDI4736) is Safe and Effective in Treatment of Chemo Refractory Advanced Biliary Tract Cancers Recruiting USA 0
NCT04914286 Phase Ib/II GFH018 + Toripalimab-tpzi A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors Completed AUS 1
NCT04919642 Phase II Tinengotinib Study to Evaluate the Efficacy and Safety of TT-00420 in Cholangiocarcinoma Completed USA 0
NCT04972981 Phase I ADCT-901 A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors Active, not recruiting USA | GBR | ESP 0
NCT04973163 Phase I BI 1823911 + Midazolam BI 1701963 + BI 1823911 A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation Active, not recruiting USA | GBR | ESP | BEL 0
NCT05001282 Phase Ib/II ELU001 A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRalpha) Terminated USA 0
NCT05007106 Phase II MK-7684A + Paclitaxel Cisplatin + Fluorouracil + MK-7684A Pembrolizumab Lenvatinib + MK-7684A MK-7684A MK-7684A With or Without Other Anticancer Therapies in Participants With Selected Solid Tumors (MK-7684A-005) (KEYVIBE-005) Active, not recruiting USA | TUR | POL | NLD | ITA | ISR | FRA | ESP | DEU | CAN 5
NCT05123482 Phase Ib/II AZD8205 First in Human Study to Evaluate AZD8205 in Patients With Advanced or Metastatic Solid Malignancies Recruiting USA | POL | NLD | ITA | HUN | GBR | ESP | CAN | BEL | AUS 5
NCT05176665 Phase Ib/II EMB-01 EMB-01 in Patients With Advanced/Metastatic Gastrointestinal Cancers Recruiting USA 1
NCT05194072 Phase I SGN-B7H4V A Study of SGN-B7H4V in Advanced Solid Tumors Recruiting USA | ITA | GBR | ESP | DEU | CAN 0
NCT05211323 Phase II Cisplatin + Gemcitabine Atezolizumab + Bevacizumab + Cisplatin + Gemcitabine A Study to Determine Whether Chemotherapy, Bevazicumab, and Atezolizumab is Better Than Chemotherapy Alone in Patients With Advanced Liver Cancer Active, not recruiting USA 0
NCT05221320 Phase II Hydroxychloroquine + Ulixertinib Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies Terminated USA 0
NCT05228015 Phase I IK-930 Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors Terminated USA | GBR | AUS 0
NCT05244551 Phase I ABSK061 A Study to Assess Safety, Tolerability, and Pharmacokinetics of ABSK061 in Patients With Advanced Solid Tumors Recruiting USA 1
NCT05275478 Phase Ib/II TNG908 Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors Active, not recruiting USA | FRA 0
NCT05306444 Phase I HBM7008 CLN-418 Study on Subjects With Advanced Solid Tumors Completed USA | AUS 0
NCT05411133 Phase I ARB202 + Atezolizumab ARB202 Treatment of Cabotamig (ARB202) in Advanced Gastrointestinal Cancer Patients Recruiting AUS 1
NCT05506943 Phase II Paclitaxel CTX-009 + Paclitaxel A Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers Active, not recruiting USA 0
NCT05510427 Phase I Atezolizumab + Bevacizumab + Infigratinib Phase Ib Trial of Infigratinib In Combination With Atezolizumab And Bevacizumab for The Second-Line Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion/Amplification Withdrawn 0
NCT05512377 Phase II BI 907828 Brightline-2: A Study to Test Whether Brigimadlin (BI 907828) Helps People With Cancer in the Biliary Tract, Pancreas, Lung or Bladder Active, not recruiting USA | GBR | FRA | ESP | DEU | CHE | BEL | AUS 5
NCT05568680 Phase I SynKIR-110 SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma Recruiting USA 0
NCT05615818 Phase III Niraparib ZW25 Binimetinib + Encorafenib Futibatinib Cisplatin + Gemcitabine Neratinib + Trastuzumab Ivosidenib Personalized Medicine for Advanced Biliary Cancer Patients (SAFIR-ABC10) Recruiting GBR | FRA | BEL 0
NCT05620914 Phase I Patritumab deruxtecan A Window of Opportunity Study of Patritumab Deruxtecan in Patients With Brain Metastases (PARAMETer) Not yet recruiting USA 0
NCT05694715 Phase I Irinotecan + Niraparib Combination Therapy in Cancers With Mutations in DNA Repair Genes Recruiting USA 0
NCT05712356 Phase II CEND-1 + Cisplatin + Durvalumab + Gemcitabine Cisplatin + Durvalumab + Gemcitabine Paclitaxel Docetaxel CEND-1 + Docetaxel CEND-1 + Paclitaxel A Study of LSTA1 When Added to Standard of Care Versus Standard of Care Alone in Patients With Advanced Solid Tumors (BOLSTER) Recruiting USA | ESP 0
NCT05718557 Phase I PYX-106 Study of PYX-106 in Solid Tumors Recruiting USA | ESP | BEL 0
NCT05727176 Phase II Futibatinib Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement (FOENIX-CCA4) Recruiting USA | POL | ITA | ESP | BRA | AUS | ARG 5
NCT05784688 Phase Ib/II Pembrolizumab + TU2218 Study of TU2218 in Combination With Pembrolizumab in Patients With Advanced Solid Tumors Recruiting USA 0
NCT05848843 Phase I Adagrasib + Durvalumab A Phase I Study of Adagrasib and Durvalumab for Treatment of Advanced Non-small Cell Lung Cancers and Gastro-intestinal Cancers Harboring KRAS G12C Mutations Withdrawn USA 0
NCT05862324 Phase Ib/II TAC01-CLDN18.2 TAC T-cells for the Treatment of Claudin 18.2 Positive Solid Tumors (TACTIC-3) (TACTIC-3) Recruiting USA | CAN 0
NCT05874414 Phase Ib/II GNS561 + Trametinib Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutation Cholangiocarcinoma Recruiting USA 1
NCT05876754 Phase III Ivosidenib An Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma (ProvIDHe) Recruiting SWE | ROU | NLD | ITA | IRL | GBR | FRA | ESP | DEU | CAN | BEL | AUT | AUS 2
NCT05921760 Phase Ib/II Ipilimumab + Ivosidenib + Nivolumab Ivosidenib, Nivolumab, and Ipilimumab Combination in Previously Treated Subjects With Nonresectable or Metastatic IDH1 Mutant Cholangiocarcinoma Active, not recruiting USA | GBR 0
NCT05948475 Phase III Tinengotinib Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma (FIRST-308) Recruiting USA | POL | NLD | ITA | GBR | FRA | ESP | DEU | BEL | AUT 3
NCT05958199 Phase I NPX267 Treatment With NPX267 for Subjects With Solid Tumors Known to Express HHLA-2 Recruiting USA 0
NCT05967182 Phase II Cisplatin + Gemcitabine + Pembrolizumab A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic Cholangiocarcinoma Recruiting USA 0
NCT06178445 Phase II Cisplatin + Gemcitabine + Pembrolizumab + Trastuzumab Efficacy and Safety of GemCis Plus Trastuzumab Plus Pembrolizumab in Previously Untreated HER2-positive Biliary Tract Cancer (TRAP-BTC) Recruiting DEU 0
NCT06178588 Phase II Sacituzumab govitecan-hziy Sacituzumab Govitecan for the Treatment for Patients With Locally Advanced, Recurrent, or Metastatic Cholangiocarcinoma Recruiting USA 0
NCT06274437 Phase I BND-35 + Cetuximab BND-35 + Nivolumab BND-35 A Study of BND-35 in Participants With Advanced Solid Tumors Recruiting ISR 0
NCT06282575 Phase III Cisplatin + Durvalumab + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab Cisplatin + Durvalumab + Gemcitabine + ZW25 Cisplatin + Gemcitabine Cisplatin + Gemcitabine + Pembrolizumab + ZW25 Cisplatin + Gemcitabine + ZW25 Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer Recruiting USA | SWE | ROU | ITA | ISR | FRA | FIN | ESP | CAN | ARG 8
NCT06302621 Phase I Afatinib + Pemigatinib Pemigatinib + Afatinib in Advanced Refractory Solid Tumors Recruiting USA 0
NCT06341764 Phase II Cisplatin + Durvalumab + Gemcitabine + Tremelimumab Neo-adjuvant Chemo and Immunotherapy in The Pre-operAtive Treatment of Locally Advanced cholangIOcarciNoma Recruiting ITA 0
NCT06360354 Phase I AMG193 + Cisplatin + Gemcitabine + Pembrolizumab AMG193 + Fluorouracil + Irinotecan + Leucovorin + Oxaliplatin AMG193 + Gemcitabine + Nab-paclitaxel A Study Evaluating AMG 193 in Combination With Other Therapies in Participants With Advanced Gastrointestinal, Biliary Tract, or Pancreatic Cancers With Homozygous Methylthioadenosine Phosphorylase (MTAP)-Deletion Recruiting USA | NLD | ITA | GRC | FRA | ESP | DNK | DEU | CAN | BEL | AUS 2
NCT06399757 Phase Ib/II APL-5125 A Study to Investigate APL-5125 in Adults With Advanced Solid Tumors Recruiting USA 0
NCT06400485 Phase I AMT-676 AMT-676 in Patients With Advanced Solid Tumors Recruiting AUS 1
NCT06439485 Phase II Atezolizumab + Bevacizumab + Pemigatinib Phase II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 Fusion Not yet recruiting USA 0
NCT06440993 Phase II Cisplatin + Durvalumab + Gemcitabine Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extrahepatic Cholangiocarcinoma Recruiting DEU 0
NCT06441747 Phase II Durvalumab + Olaparib Phase II Study of the Combination of Durvalumab (MEDI4736) (PDL1 Inhibitor) and Olaparib (PARP Inhibitor) in Advanced Cholangiocarcinoma After Initial Chemotherapy and Durvalumab (BIL-PPP) Not yet recruiting AUS 0
NCT06597721 Phase I AMT-754 AMT-754 in Patients With Selected Advanced Solid Tumours Not yet recruiting AUS 0
NCT06638931 Phase II Nivolumab Agnostic Therapy in Rare Solid Tumors (ANTARES) Recruiting BRA 0